Abstract:
This multicenter real-world study from Uzbekistan evaluated cytokine-guided
postoperative immunological correction in patients with rheumatoid arthritis undergoing
total knee arthroplasty. A total of 106 patients were stratified according to dominant
cytokine profiles, including TNF-α, IL-6, and IL-1β, and received pathway-matched
biologic therapy with csDMARDs. Over 52 weeks, significant improvements were
observed in DAS28, HAQ-DI, VAS pain, CRP, ESR, and cytokine levels. Nearly half
of the patients achieved remission, and most reached low disease activity. No prosthetic
joint infections, implant failures, or deaths were recorded. These findings suggest that
cytokine-guided personalized therapy may improve postoperative recovery, disease
control, and safety in rheumatoid arthritis patients after total knee arthroplasty.
